https://biotechmorning.com/news/colorado-fda-canada-drug-importation Biotech Morning en 2026-06-16T14:22:48.550Z Colorado Just Got Permission to Buy Its Drugs From Canada https://biotechmorning.com/news/neumora-navacaprant-depression-phase-3-failure Biotech Morning en 2026-06-16T14:22:04.841Z Neumora's Depression Drug Went 0-for-3. Now It's a Penny Stock. https://biotechmorning.com/news/intellia-crispr-hae-one-shot-cure Biotech Morning en 2026-06-16T14:21:08.719Z One Shot to Silence a Disease Forever https://biotechmorning.com/news/europe-clinical-trial-registry-transparency-problem Biotech Morning en 2026-06-16T14:20:13.701Z Europe's Clinical Trial Registry Has a Transparency Problem Nobody's Fixing https://biotechmorning.com/news/spyre-spy002-phase-2-ulcerative-colitis-results Biotech Morning en 2026-06-16T14:19:17.582Z Spyre Just Dropped the Best Report Card in UC's Hottest Drug Class https://biotechmorning.com/news/adaptive-biotechnologies-splitting-diagnostics-drug-discovery Biotech Morning en 2026-06-16T14:18:24.118Z Adaptive Biotech Is Breaking Up With Itself https://biotechmorning.com/news/medicare-subcutaneous-keytruda-opdivo-pricing-loophole Biotech Morning en 2026-06-16T14:17:28.995Z The Escape Hatch That Medicare Wants to Slam Shut https://biotechmorning.com/news/chiesi-kalvista-oral-hae-treatment-acquisition Biotech Morning en 2026-06-16T14:16:36.696Z The $1.9 Billion Pill That Replaced a Needle https://biotechmorning.com/news/ucb-candid-therapeutics-2-billion-acquisition-3 Biotech Morning en 2026-06-16T14:15:37.432Z UCB Just Bet $2 Billion on a Cancer Drug That Might Cure Autoimmune Disease https://biotechmorning.com/news/lilly-jaypirca-cll-frontline-surprise Biotech Morning en 2026-06-15T14:28:16.646Z Lilly's Cancer Drug Just Aced a Test Nobody Expected It to Pass https://biotechmorning.com/news/merck-terns-pharmaceuticals-acquisition-6-7-billion Biotech Morning en 2026-06-15T14:27:24.299Z Merck Just Paid $6.7 Billion for a Company That Was Worth $300 Million Two Years Ago https://biotechmorning.com/news/allogene-off-the-shelf-car-t-breaks-wall-street Biotech Morning en 2026-06-15T14:26:30.116Z The $4,000 Cancer Therapy That Just Broke Wall Street https://biotechmorning.com/news/pfizer-mrna-flu-vaccine-beats-standard-shot Biotech Morning en 2026-06-15T14:25:31.567Z Pfizer's Flu Shot Just Beat the Flu Shot https://biotechmorning.com/news/legend-biotech-in-vivo-car-t-proof-of-concept Biotech Morning en 2026-06-15T14:24:43.136Z What If Your Body Could Build Its Own Cancer-Killing Cells? https://biotechmorning.com/news/asundexian-fxia-stroke-prevention-phase-3 Biotech Morning en 2026-06-15T14:23:43.269Z The Blood Thinner That Forgot How to Cause Bleeding https://biotechmorning.com/news/revolution-medicines-pancreatic-cancer-survival-breakthrough Biotech Morning en 2026-06-15T14:22:51.410Z The Pill That's Rewriting Pancreatic Cancer's Brutal Math https://biotechmorning.com/news/biogen-apellis-acquisition-ophthalmology Biotech Morning en 2026-06-15T14:22:03.328Z Biogen Just Dropped $5.6 Billion on an Eye Drug Company. Here's Why. https://biotechmorning.com/news/gilead-arcellx-7-8-billion-car-t-acquisition Biotech Morning en 2026-06-15T14:21:07.382Z Gilead Just Spent $7.8 Billion on a Tiny Protein That Could Reshape Cancer Treatment https://biotechmorning.com/news/sun-pharma-organon-acquisition-indian-pharma Biotech Morning en 2026-06-15T14:20:11.317Z The $11.75 Billion Bet That Rewrites Indian Pharma's Playbook https://biotechmorning.com/news/jj-posdinemab-alzheimer-tau-failure Biotech Morning en 2026-06-15T14:19:12.168Z The $5 Billion Alzheimer's Bet That Just Went to Zero